Taken together, this study extends previous findings of visuo-spatial alterations in mouse models of AD and other tauopathies [4] by demonstrating uniquely that the accumulation of a specific, pathogenic N-terminal-cleaved form of tau (i.e., NH2htau) in the V1 area of Tg2576 AD mice translates into functional impairments of their visual performance (i.e., reduced visual acuity) and that this diminution is significantly recovered by treatment with 12A12mAb. The gene discussed is MAPT; the disease is Alzheimer disease.